Small-molecule murine double minute 2 (mdm2)/p53 binding antagonists and histone deacetylase (HDAC) inhibitors are currently in clinical trials for cancer, and HDAC inhibitor suberoylanilide hydroxamic acid (SAHA; vorinostat; Zolinza) has been approved for the treatment of cutaneous T-cell lymphoma.1 The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.